Company intelligence / Profile preview
Orpha Labs
Zug, Zug, Switzerlandnewswire.ca ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Phase 3
01
Overview
Orpha Labs is advancing ORL‑101, an ultra-pure L-fucose formulation for the treatment of LAD-II. ORL‑101 has received FDA Rare Pediatric Disease Designation and is available under compassionate use in Israel. A Phase 3 trial is planned or ongoing. Other pipeline programs are in earlier stages targeting additional rare metabolic disorders.
- Therapeutic areas
- ImmunologyMetabolic Disorders
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →Beyond the preview
Go deeper on Orpha Labs.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Orpha Labs.